Peginterferon alfa-2a + ribavirin

DRUG2 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Hospital Clinico Universitario San Cecilio

Conditions

Chronic Hepatitis cCirrhosis, LiverFibrosis, LiverHIV InfectionsHepatic CirrhosisHepatitis C

Phase 3

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

CompletedNCT00006164

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver +1

Start: 2000-06-30End: 2009-10-31Updated: 2020-05-12

Phase 4

Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4

CompletedNCT00612755

Hospital Clinico Universitario San CecilioHepatitis C, HIV Infections

Start: 2005-10-31End: 2008-01-31Updated: 2008-02-12

Related Papers

Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.

2014-05-073 citations

Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.

2010-11-0244 citations

Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.

2010-01-1221 citations

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

2008-12-01303 citations